Travel
Trials begin for new anti-COVID ‘cocktail’ drug
An alternative anti-coronavirus jab aimed at protecting those who cannot receive vaccines will enter major trials this weekend.
The drug is made by AstraZeneca, the pharmaceutical company that worked with Oxford University in the UK to develop a general vaccine.
The alternative injection was developed using antibodies produced by a single coronavirus patient in the US.
The arm jab takes effect immediately and could protect people against transmission for six months to a year.
If trials prove successful, it could be used to safeguard those who cannot be administered vaccines because of their health.
